← Global Bio-chem Technology Group Co. Ltd / ADR (GBCMF) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Global Bio-chem Technology Group Co. Ltd / ADR (GBCMF)
Biotechnology · market cap $84M · as of 2026-07-15
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
None scheduled
Pipeline
1
programs
Upcoming events
0
next 90d+
Dossier
Ready
cached
Non-US-listed company. Financial statements and forensic scores here come from US SEC filings (10-K/10-Q), which foreign issuers don’t file — those sections may be blank. The catalyst calendar, pipeline, approval odds, price context and (where covered) analyst targets still apply.
Global Bio-chem Technology Group Co. Ltd (GBCMF) is a biotechnology company with 1,890 employees and an $84M market cap. Its pipeline includes Fezolinetant in Phase 3 for menopause and Enzalutamide in Phase 2 for prostate cancer. Financial details, share count, cash position, and runway are not disclosed in available data.
The catalyst path
No upcoming catalysts in our calendar.
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Fezolinetant | Phase 3 | Menopause |
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for GBCMF (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 1 registered trial on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.